AZN
AstraZeneca PLCNYSEHealthcare$203.49+1.37%OpenMarket Cap: $157.73B
As of 2026-04-06
Valuation
P/E (TTM)
15.43
PEG
0.34
P/B
6.44
P/S
5.26
EV/EBITDA
16.82
DCF Value
$1,173.12
FCF Yield
3.3%
Div Yield
1.5%
Margins & Returns
Gross Margin
78.2%
Operating Margin
23.3%
Net Margin
17.4%
ROE
23.0%
ROA
18.9%
ROIC
13.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $15.50B | 79.9% | $2.98B | $2.33B | $2.96 | — |
| FY 2025 | $58.74B | 81.9% | $13.74B | $10.26B | $13.08 | $1.57 |
| Q3 2025 | $15.19B | 81.6% | $3.58B | $2.53B | $3.24 | $0.52 |
| Q2 2025 | $14.46B | 82.9% | $3.51B | $2.45B | $3.14 | — |
| Q1 2025 | $13.59B | 83.5% | $3.67B | $2.92B | $3.74 | $1.05 |
| Q4 2024 | $14.89B | 81.7% | $2.04B | $1.50B | $1.92 | — |
| FY 2024 | $54.07B | 81.1% | $10.00B | $7.04B | $4.50 | $1.48 |
| Q3 2024 | $13.56B | 77.3% | $2.11B | $1.43B | $1.84 | $0.50 |
| Q2 2024 | $12.94B | 83.1% | $2.75B | $1.93B | $2.48 | — |
| Q1 2024 | $12.68B | 82.5% | $3.12B | $2.18B | $2.80 | $0.99 |
| Q4 2023 | $12.02B | 80.8% | $1.23B | $960.0M | $1.22 | — |
| FY 2023 | $45.81B | 82.0% | $8.19B | $5.96B | $7.62 | $1.43 |